Severe Acute Respiratory Syndrome Coronavirus 2 (SARS‑CoV‑2) Research

1. Overview

Severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) is a positive‑sense single‑stranded RNA virus belonging to genus Betacoronavirus, subgenus Sarbecovirus. It is the causative agent of coronavirus disease 2019 (COVID‑19). First reported in Wuhan, China, in late 2019, SARS‑CoV‑2 spreads predominantly via respiratory droplets and aerosols. The incubation period commonly ranges from 2‑14 days. Infected persons can transmit the virus even before symptom onset. Clinical presentations vary widely: asymptomatic infection, mild upper‑respiratory symptoms, moderate pneumonia, or severe disease with acute respiratory distress syndrome (ARDS), cytokine storm, multi‑organ injury and death. Age and underlying comorbidities are major risk factors for severe outcomes. The virus has generated multiple variant lineages with altered transmissibility, immune evasion, or clinical characteristics.

2. Background Information

2.1 What is SARS‑CoV‑2?

SARS‑CoV‑2 is an enveloped positive‑sense single‑stranded RNA virus within Coronaviridae family, Orthocoronavirinae subfamily, Betacoronavirus genus, Sarbecovirus subgenus. Its genome size is approximately 29.9 kb. Genome architecture includes a 5'‑UTR, large replicase ORF1a/ORF1b region, structural‑protein genes, accessory open reading frames, a 3'‑UTR and poly(A) tail.

The 5’ two‑thirds of the genome encodes pp1a and pp1ab polyproteins, cleaved by viral proteases to yield 16 non‑structural proteins (nsp1‑nsp16). These nsps assemble replication‑transcription complexes (RTC) for viral RNA synthesis, modification, proofreading and host immune antagonism.

The 3’ genomic segment encodes four canonical structural proteins: Spike (S), Envelope (E), Membrane (M), Nucleocapsid (N), plus multiple accessory proteins (ORF3a, ORF3b, ORF6, ORF7a, ORF7b, ORF8, ORF9b etc.). Spike mediates host‑cell receptor recognition and membrane fusion. N protein packages viral genomic RNA. M and E participate in virion morphogenesis, assembly and egress.

2.2 SARS‑CoV‑2 Genome & Variants

Genome Region	Major Products	Main Function
ORF1a	pp1a → nsp1‑11	Replication complex assembly, host‑cell modulation
ORF1b	pp1ab → nsp12‑16	RNA‑dependent RNA synthesis, RNA proofreading & modification
S	Spike glycoprotein	Receptor binding, host‑membrane fusion
ORF3a	ORF3a accessory protein	Ion‑channel activity, host‑pathogen interaction
E	Envelope protein	Virion assembly, ion‑channel function
M	Membrane protein	Virion morphogenesis & assembly
ORF6	ORF6	Host‑immune antagonism
ORF7a / ORF7b	Accessory proteins	Host‑cell interaction, immune modulation
ORF8	ORF8	Immune evasion, host‑protein degradation
N	Nucleocapsid protein	Viral RNA binding, genome packaging

Major Variant Lineages

Variant Group	Key Spike Mutations	Phenotypic Features
Alpha (B.1.1.7)	Δ69‑70, Δ144, N501Y, A570D, P681H, T716I, S982A, D1118H	Increased transmissibility
Beta (B.1.351)	D80A, D215G, Δ242‑244, K417N, E484K, N501Y	Enhanced antibody escape
Gamma (P.1)	L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, H655Y	Antibody escape & increased transmission
Delta (B.1.617.2)	T19R, Δ156‑157, R158G, L452R, T478K, P681R, D950N	Strongly enhanced transmissibility
Omicron (B.1.1.529)	Extensive spike‑protein mutations including many within RBD	Marked immune evasion, altered tissue tropism

2.3 SARS‑CoV‑2 Structural Proteins

Four major structural proteins: Spike (S), Envelope (E), Membrane (M), Nucleocapsid (N). Spike glycoprotein is the main surface antigen and mediates host‑cell entry. S protein is cleaved into S1 and S2 subunits. S1 contains Receptor‑Binding Domain (RBD) for ACE2 receptor binding; S2 executes membrane‑fusion events. N protein binds viral RNA for genome packaging, also participates in replication‑transcription and host‑cell interactions. M and E coordinate virion assembly, budding and release.

Structural Protein Targets

Protein	Full name	Main Function
S	Spike protein	ACE2 receptor binding and membrane fusion
S1	Spike S1 subunit	Receptor recognition
RBD	Receptor‑binding domain	Direct ACE2 interaction
S2	Spike S2 subunit	Membrane fusion machinery
N	Nucleocapsid protein	RNA binding, genome packaging
M	Membrane protein	Virion assembly
E	Envelope protein	Assembly, release, viroporin activity

2.4 Mechanism of Cell Entry and Replication Cycle

2.4.1 Receptor Recognition and Attachment

SARS‑CoV‑2 Spike protein binds human angiotensin‑converting enzyme 2 (ACE2). RBD within S1 is responsible for high‑affinity interaction with ACE2. Host co‑factors include TMPRSS2, cathepsins, heparan sulfate and other attachment molecules; ACE2 remains the primary functional receptor.

2.4.2 Spike Protein Priming and Activation

Two major proteolytic routes: cell‑surface TMPRSS2 cleavage of Spike after ACE2 engagement triggers early plasma‑membrane fusion; alternatively virions are endocytosed and endosomal cathepsin‑B/L mediate S‑protein activation inside endosomes for fusion with endosomal membrane.

2.4.3 Viral RNA Replication & Transcription

After fusion and uncoating, positive‑sense genomic RNA is released into cytosol. Host ribosomes translate pp1a and pp1ab polyproteins. Viral proteases (Mpro/nsp5, PLpro/nsp3) process polyproteins to produce nsp1‑16 non‑structural proteins. These assemble RTC replication‑transcription complexes for negative‑strand intermediate synthesis, then produce full‑length genomic RNA plus nested set of subgenomic RNAs coding structural and accessory proteins.

2.4.4 Virion Assembly and Egress

New‑synthesized positive‑sense genomic RNA complexes with N protein to form ribonucleoprotein complex. S, M and E structural proteins traffic through secretory pathway to ERGIC compartment. Virion assembly takes place at ERGIC membrane; complete virions are packaged inside transport vesicles and secreted from infected cells.

2.5 Clinical Symptoms and Disease Spectrum

SARS‑CoV‑2 infection manifests broad clinical spectrum:

• Asymptomatic infection
• Mild disease: fever, dry cough, sore throat, fatigue, myalgia, headache, loss or alteration of taste/smell, rhinorrhoea, gastrointestinal discomfort
• Moderate disease: lower‑respiratory‑tract involvement, pneumonia, hypoxia
• Severe disease: severe pneumonia, acute respiratory distress syndrome ARDS, cytokine release syndrome, thrombotic events, multi‑organ‑system failure

Long COVID / post‑COVID‑19 syndrome can persist weeks‑months after acute infection, including fatigue, dyspnea, cognitive impairment and diverse systemic manifestations.

2.6 Therapeutic Intervention Targets

2.6.1 Viral‑encoded Targets

Target	Protein	Biological Role
Spike (S)	Spike glycoprotein	Receptor binding & membrane fusion
RBD	Spike RBD domain	ACE2 interaction
S1 subunit	Spike S1	Receptor recognition
S2 subunit	Spike S2	Membrane fusion
N	Nucleocapsid	RNA binding & genome packaging
M	Membrane protein	Virion assembly
E	Envelope protein	Assembly, viroporin activity
Mpro / 3CLpro	nsp5	Polyprotein processing
PLpro	nsp3	Polyprotein processing & de‑ISGylation
RdRp	nsp12	Viral RNA synthesis
Helicase	nsp13	RNA unwinding
ExoN	nsp14	RNA proofreading
nsp16	nsp16	mRNA cap‑2'O‑methylation, immune evasion

2.6.2 Host Receptors & Entry‑Related Factors

Host Target	Type	Role in Infection
ACE2	Receptor	Primary virus receptor for Spike binding
TMPRSS2	Serine protease	Spike protein priming at cell‑surface
Cathepsin L	Cysteine protease	Endosomal S‑protein activation
Cathepsin B	Cysteine protease	Endosomal S‑protein activation
DC‑SIGN / L‑SIGN	C‑type lectin attachment factors	Facilitate viral attachment
Heparan sulfate	Cell‑surface glycan	Virus attachment co‑factor

2.6.3 Host Innate‑Immune & Signalling Pathways

Pathway	Key Targets	Biological Role
ACE2‑RAAS axis	ACE2, Ang‑II, AT1R	Virus entry; renin‑angiotensin dysregulation
RIG‑I/MDA5‑MAVS	RIG‑I, MDA5, MAVS	Cytosolic viral RNA sensing
TBK1‑IRF3	TBK1, IRF3	Type‑I interferon induction
JAK‑STAT signalling	JAK1, TYK2, STAT1/STAT2	Interferon downstream signalling
TLR‑mediated sensing	TLR3, TLR4, TLR7/8	Endosomal nucleic‑acid sensing
NF‑κB pathway	IKK complex, p65	Pro‑inflammatory gene expression
MAPK inflammatory cascade	ERK, JNK, p38	Stress‑response & inflammation

2.6.4 Cytokine / Chemokine Immune Targets

Target	Category	Major Biological Role
IFN‑α / IFN‑β	Type‑I interferon	Broad antiviral state induction
IFN‑γ	Type‑II interferon	Cell‑mediated immunity
IL‑6	Pro‑inflammatory cytokine	Central mediator of hyper‑inflammation
IL‑1β	Pro‑inflammatory cytokine	Inflammasome‑driven inflammation
TNF‑α	Pro‑inflammatory cytokine	Multiple inflammatory responses
CXCL10	Chemokine	Recruit immune effector cells
CCL2	Chemokine	Monocyte / macrophage recruitment

2.7 Vaccine Platforms

Multiple vaccine modalities deployed against SARS‑CoV‑2: mRNA vaccines, viral‑vector vaccines, inactivated whole‑virus vaccines, recombinant protein‑subunit vaccines, DNA‑based vaccines. Most vaccine platforms focus immune responses against Spike glycoprotein, especially RBD domain, to induce neutralizing‑antibody and T‑cell immunity. Variants with extensive spike mutations impose challenges for vaccine effectiveness, driving updates of vaccine antigen composition.

• mRNA vaccines: lipid‑nanoparticle‑delivered mRNA encoding full‑length stabilized Spike protein
• Replication‑defective viral‑vector vaccines: adenovirus vectors encoding Spike antigen
• Inactivated‑virus vaccines: chemically inactivated whole SARS‑CoV‑2 virions
• Recombinant‑protein subunit vaccines: purified Spike / RBD protein antigens plus adjuvant
• DNA vaccines: plasmid‑DNA encoding spike antigen

2.8 Antiviral and Immunomodulatory Therapeutics

2.8.1 Virus‑targeted therapeutics

Target	Drug / Agent	Mechanism of Action
Spike‑ACE2 interaction	Neutralizing monoclonal antibodies	Block receptor attachment; neutralize virions
Mpro (nsp5)	Nirmatrelvir (ritonavir‑boosted Paxlovid)	Main‑protease inhibition, block polyprotein processing
RdRp nsp12	Remdesivir	Nucleotide analogue; inhibit viral RNA synthesis
RdRp nsp12	Molnupiravir	Nucleoside analogue, introduce viral mutagenesis

2.8.2 Host‑targeted therapeutics

Target Pathway / Protein	Drug / Agent	Mechanism of Action
TMPRSS2	Camostat mesylate	Inhibit host serine‑protease spike priming
IL‑6 receptor	Tocilizumab / Sarilumab	Block IL‑6‑mediated inflammatory signalling
JAK‑STAT signalling	Baricitinib	JAK kinase inhibitor, suppress cytokine signalling
Glucocorticoid receptor	Dexamethasone	Broad immunosuppressive / anti‑inflammatory effects

3. Related Products & Services

• Recombinant antigens and receptors (Spike, RBD, N protein, ACE2 etc.)
• Antibody portfolio: neutralizing antibodies, S/N‑protein specific antibodies
• Detection assay kits for antigen / antibody testing
• Recombinant protein custom expression service
• Custom antibody generation service

4. Resources

Global SARS‑CoV‑2 sequence database GISAID; WHO COVID‑19 technical reports; PDB structural repository for coronavirus protein structures.

5. References

1. Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270‑273.
2. Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579(7798):265‑269.
3. Hoffmann M, Kleine‑Weber H, Schroeder S, et al. SARS‑CoV‑2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181(2):271‑280.e8.
4. Wrapp D, Wang N, Corbett KS, et al. Cryo‑EM structure of the 2019‑nCoV spike in the prefusion conformation. Science. 2020;367(6483):1260‑1263.
5. Yan R, Zhang Y, Li Y, et al. Structural basis for the recognition of SARS‑CoV‑2 by human ACE2. Science. 2020;367(6485):1444‑1448.
6. Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019‑nCoV) in vitro. Cell Res. 2020;30(3):269‑271.
7. Owen DR, Allerton CMN, Anderson AS, et al. An oral SARS‑CoV‑2 Mpro inhibitor clinical candidate for the treatment of COVID‑19. Science. 2021;374(6575):1586‑1593.
8. Jonsson CM, Jain A. Molnupiravir: A Review of Its Mechanism of Action, Efficacy, and Safety for the Treatment of COVID‑19. Pharmacotherapy. 2022;42(3):247‑258.
9. RECOVERY Collaborative Group. Dexamethasone in Hospitalized Patients with Covid‑19. N Engl J Med. 2021;384(8):693‑704.
10. RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID‑19 (RECOVERY): a randomised, controlled, open‑label, platform trial. Lancet. 2021;397(10285):1637‑1647.
11. Bar‑Ziv A, Decaluwe H. COVID‑19 vaccines‑an overview of vaccine platforms, efficacy and variant responses. Curr Opin Virol. 2022;53:101209.
12. Harvey WT, Carabelli AM, Jackson B, et al. SARS‑CoV‑2 variants, spike mutations and immune escape. Nat Rev Microbiol. 2021;19(7):409‑424.
13. V’kovski P, Kratzel A, Steiner S, et al. Coronavirus biology and replication: implications for SARS‑CoV‑2. Nat Rev Microbiol. 2021;19(3):155‑170.